Tags

Type your tag names separated by a space and hit enter

Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Contraception. 1995 Sep; 52(3):143-9.C

Abstract

Data from a previous study, designed to compare metabolic risk markers for cardiovascular disease in non-users and oral contraceptive (OC) users, were analysed to evaluate the influence of OC composition on blood pressure. Healthy, female volunteers (1189 women) either not using OC (non-users) or currently using one of six different combined formulations (users) were compared. Combinations studied contained 30-40 micrograms ethinyl estradiol combined with the progestins levonorgestrel, norethindrone (at two and three different doses, respectively) or desogestrel. After statistical standardisation to account for the significantly greater age of the non-users and longer duration of OC use amongst the levonorgestrel combination users, mean blood pressure was higher, compared with non-users, in users of monophasic or triphasic levonorgestrel combinations (systolic: +4.3 mmHg (p < 0.001) and +2.7 mmHg (p < 0.001), respectively; diastolic: +2.6 mmHg (p < 0.001) and +2.3 mmHg (p < 0.05), respectively). Blood pressures in users of monophasic norethindrone and desogestrel combinations were not significantly raised and there was no increase in the proportion of women with abnormal values. Diastolic and systolic blood pressures were positively associated with oral glucose tolerance test insulin response (r = 0.11 (p < 0.01) and r = 0.15 (p < 0.001), respectively) in users but not in non-users. Currently used OC containing norethindrone or desogestrel progestins have little impact on blood pressure. Their correlated reduction in impact on insulin concentrations, though small, suggests common mechanisms through which OC affect blood pressure and insulin.

Authors+Show Affiliations

Wynn Department of Metabolic Medicine, National Heart and Lung Institute, London, UK.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

7587185

Citation

Godsland, I F., et al. "Relationships Between Blood Pressure, Oral Contraceptive Use and Metabolic Risk Markers for Cardiovascular Disease." Contraception, vol. 52, no. 3, 1995, pp. 143-9.
Godsland IF, Crook D, Devenport M, et al. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception. 1995;52(3):143-9.
Godsland, I. F., Crook, D., Devenport, M., & Wynn, V. (1995). Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception, 52(3), 143-9.
Godsland IF, et al. Relationships Between Blood Pressure, Oral Contraceptive Use and Metabolic Risk Markers for Cardiovascular Disease. Contraception. 1995;52(3):143-9. PubMed PMID: 7587185.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. AU - Godsland,I F, AU - Crook,D, AU - Devenport,M, AU - Wynn,V, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez KW - Biology KW - Blood Pressure KW - Carbohydrate Metabolic Effects KW - Cardiovascular Effects KW - Contraception KW - Contraceptive Agents, Female--administraction and dosage KW - Contraceptive Agents, Progestin--administraction and dosage KW - Contraceptive Agents--administraction and dosage KW - Contraceptive Methods--pharmacodynamics KW - Contraceptive Methods--side effects KW - Correlation Studies KW - Desogestrel--administraction and dosage KW - Developed Countries KW - England KW - Europe KW - Family Planning KW - Glucose Metabolism Effects KW - Hemic System KW - Levonorgestrel--administraction and dosage KW - Lipid Metabolic Effects KW - Lipids KW - Metabolic Effects KW - Norethindrone--administraction and dosage KW - Northern Europe KW - Oral Contraceptives, Combined--pharmacodynamics KW - Oral Contraceptives, Combined--side effects KW - Oral Contraceptives--pharmacodynamics KW - Oral Contraceptives--side effects KW - Physiology KW - Research Methodology KW - Research Report KW - Statistical Studies KW - Studies KW - United Kingdom SP - 143 EP - 9 JF - Contraception JO - Contraception VL - 52 IS - 3 N2 - Data from a previous study, designed to compare metabolic risk markers for cardiovascular disease in non-users and oral contraceptive (OC) users, were analysed to evaluate the influence of OC composition on blood pressure. Healthy, female volunteers (1189 women) either not using OC (non-users) or currently using one of six different combined formulations (users) were compared. Combinations studied contained 30-40 micrograms ethinyl estradiol combined with the progestins levonorgestrel, norethindrone (at two and three different doses, respectively) or desogestrel. After statistical standardisation to account for the significantly greater age of the non-users and longer duration of OC use amongst the levonorgestrel combination users, mean blood pressure was higher, compared with non-users, in users of monophasic or triphasic levonorgestrel combinations (systolic: +4.3 mmHg (p < 0.001) and +2.7 mmHg (p < 0.001), respectively; diastolic: +2.6 mmHg (p < 0.001) and +2.3 mmHg (p < 0.05), respectively). Blood pressures in users of monophasic norethindrone and desogestrel combinations were not significantly raised and there was no increase in the proportion of women with abnormal values. Diastolic and systolic blood pressures were positively associated with oral glucose tolerance test insulin response (r = 0.11 (p < 0.01) and r = 0.15 (p < 0.001), respectively) in users but not in non-users. Currently used OC containing norethindrone or desogestrel progestins have little impact on blood pressure. Their correlated reduction in impact on insulin concentrations, though small, suggests common mechanisms through which OC affect blood pressure and insulin. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/7587185/Relationships_between_blood_pressure_oral_contraceptive_use_and_metabolic_risk_markers_for_cardiovascular_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010782495001532 DB - PRIME DP - Unbound Medicine ER -